drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00357 | DB09039 | 1,051 | 1,670 | [
"DDInter71",
"DDInter629"
] | Aminoglutethimide | Eliglustat | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Moderate | 1 | [
[
[
1051,
24,
1670
]
],
[
[
1051,
24,
479
],
[
479,
23,
1670
]
],
[
[
1051,
24,
1135
],
[
1135,
62,
1670
]
],
[
[
1051,
24,
1409
],
[
1409... | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
... | Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol a... |
DB00682 | DB09330 | 126 | 985 | [
"DDInter1951",
"DDInter1352"
] | Warfarin | Osimertinib | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
126,
24,
985
]
],
[
[
126,
62,
168
],
[
168,
23,
985
]
],
[
[
126,
25,
1247
],
[
1247,
23,
985
]
],
[
[
126,
24,
1478
],
[
1478,
... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"... | Warfarin may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Warfarin may lead to a major life threatening interaction when taken with Sulfamethoxazole and Sulfamethoxazole may c... |
DB08875 | DB09080 | 1,618 | 144 | [
"DDInter262",
"DDInter1331"
] | Cabozantinib | Olodaterol | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
1618,
24,
144
]
],
[
[
1618,
62,
1247
],
[
1247,
23,
144
]
],
[
[
1618,
64,
956
],
[
956,
24,
144
]
],
[
[
1618,
63,
543
],
[
543,
... | [
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Cabozantinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Cabozantinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Olodaterol
Cabozantinib may lead to a major life threatening interaction when taken with Norfloxacin and Norfloxa... |
DB00397 | DB09564 | 1,466 | 1,296 | [
"DDInter1458",
"DDInter930"
] | Phenylpropanolamine | Insulin degludec | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
1466,
24,
1296
]
],
[
[
1466,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
1466,
63,
1645
],
[
1645,
24,
1296
]
],
[
[
1466,
64,
1230
],
[
12... | [
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tol... | Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00959 | DB01097 | 1,486 | 1,377 | [
"DDInter1191",
"DDInter1033"
] | Methylprednisolone | Leflunomide | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
1486,
25,
1377
]
],
[
[
1486,
5,
11577
],
[
11577,
44,
1377
]
],
[
[
1486,
21,
29231
],
[
29231,
60,
1377
]
],
[
[
1486,
62,
1461
],
[
... | [
[
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) treats {v} (Disease)",
"rheumatoid arthritis"
],
[
"rheumatoid arthritis",
"{u} (... | Methylprednisolone (Compound) treats rheumatoid arthritis (Disease) and rheumatoid arthritis (Disease) is treated by Leflunomide (Compound)
Methylprednisolone (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Leflunomide (Compound)
Methylprednisolone may cause a minor inte... |
DB06688 | DB14783 | 1,430 | 287 | [
"DDInter1677",
"DDInter574"
] | Sipuleucel-T | Diroximel fumarate | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
1430,
24,
287
]
],
[
[
1430,
63,
1101
],
[
1101,
24,
287
]
],
[
[
1430,
24,
812
],
[
812,
24,
287
]
],
[
[
1430,
24,
1510
],
[
1510,
... | [
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
... | Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Siltuxima... |
DB00304 | DB01098 | 1,657 | 14 | [
"DDInter508",
"DDInter1622"
] | Desogestrel | Rosuvastatin | Desogestrel, a prodrug, is a third generation progestogen and hence, a member of the gonane family which was largely used in Europe before being approved in the US and Canada. It was firstly generated from a study that showed that 11-beta and 11-alkylidene substituent in nortestosterone can enhance the biological activ... | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Minor | 0 | [
[
[
1657,
23,
14
]
],
[
[
1657,
21,
29579
],
[
29579,
60,
14
]
],
[
[
1657,
1,
1336
],
[
1336,
23,
14
]
],
[
[
1657,
25,
1040
],
[
1040,
... | [
[
[
"Desogestrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Desogestrel",
"{u} (Compound) causes {v} (Side Effect)",
"Breast disorder"
],
[
"Breast disorder",
"{u} (Side E... | Desogestrel (Compound) causes Breast disorder (Side Effect) and Breast disorder (Side Effect) is caused by Rosuvastatin (Compound)
Desogestrel (Compound) resembles Etonogestrel (Compound) and Etonogestrel may cause a minor interaction that can limit clinical effects when taken with Rosuvastatin
Desogestrel may lead to ... |
DB09045 | DB11255 | 52 | 1,371 | [
"DDInter607",
"DDInter374"
] | Dulaglutide | Chromium picolinate | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Chromium picolinate has a chemical formula CrPic3 and reddish-pink color. It is a coordination complex consisting of chromium(III) and picolinic acid. Chromium picolinate is used as a nutritional supplement for optimal insulin function in patients with Type 2 diabetes or promotion of weight loss. Chromium ions are show... | Moderate | 1 | [
[
[
52,
24,
1371
]
],
[
[
52,
63,
245
],
[
245,
24,
1371
]
],
[
[
52,
24,
1296
],
[
1296,
24,
1371
]
],
[
[
52,
62,
170
],
[
170,
24... | [
[
[
"Dulaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Dulaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
... | Dulaglutide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Dulaglutide may cause a moderate interaction that could exacerbate diseases when taken with Insulin ... |
DB08881 | DB13074 | 868 | 877 | [
"DDInter1925",
"DDInter1110"
] | Vemurafenib | Macimorelin | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
868,
25,
877
]
],
[
[
868,
62,
112
],
[
112,
23,
877
]
],
[
[
868,
24,
1320
],
[
1320,
24,
877
]
],
[
[
868,
64,
651
],
[
651,
2... | [
[
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Vemurafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Ela... |
DB01156 | DB08824 | 593 | 591 | [
"DDInter252",
"DDInter959"
] | Bupropion | Ioflupane I-123 | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Ioflupane (I-123) is a radiopharmaceutical used to image dopamine neurons and diagnose Parkinsonian syndromes. | Moderate | 1 | [
[
[
593,
24,
591
]
],
[
[
593,
6,
2437
],
[
2437,
45,
591
]
],
[
[
593,
21,
29305
],
[
29305,
60,
591
]
],
[
[
593,
64,
109
],
[
109,
... | [
[
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioflupane I-123"
]
],
[
[
"Bupropion",
"{u} (Compound) binds {v} (Gene)",
"SLC6A3"
],
[
"SLC6A3",
"{u} (Gene) is bound by {v} (Compound... | Bupropion (Compound) binds SLC6A3 (Gene) and SLC6A3 (Gene) is bound by Ioflupane I-123 (Compound)
Bupropion (Compound) causes Dysgeusia (Side Effect) and Dysgeusia (Side Effect) is caused by Ioflupane I-123 (Compound)
Bupropion may lead to a major life threatening interaction when taken with Duloxetine and Duloxetine m... |
DB00365 | DB06203 | 839 | 1,002 | [
"DDInter842",
"DDInter51"
] | Grepafloxacin | Alogliptin | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
839,
24,
1002
]
],
[
[
839,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
839,
25,
401
],
[
401,
24,
1002
]
],
[
[
839,
64,
521
],
[
521,
... | [
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
... | Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Grepafloxacin may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could ex... |
DB00780 | DB01088 | 551 | 714 | [
"DDInter1440",
"DDInter908"
] | Phenelzine | Iloprost | Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name o... | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Moderate | 1 | [
[
[
551,
24,
714
]
],
[
[
551,
63,
1648
],
[
1648,
24,
714
]
],
[
[
551,
24,
1637
],
[
1637,
63,
714
]
],
[
[
551,
25,
1445
],
[
1445,
... | [
[
[
"Phenelzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Phenelzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
... | Phenelzine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Phenelzine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite and Amyl... |
DB00153 | DB00241 | 1,331 | 288 | [
"DDInter662",
"DDInter257"
] | Ergocalciferol | Butalbital | Ergocalciferol is an inactivated vitamin D analog. It is synthesized by some plants in the presence of UVB light. The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as the main causative factor for the development of rickets. Ergocalciferol was isolat... | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | Moderate | 1 | [
[
[
1331,
24,
288
]
],
[
[
1331,
24,
1023
],
[
1023,
1,
288
]
],
[
[
1331,
24,
536
],
[
536,
40,
288
]
],
[
[
1331,
23,
752
],
[
752,
... | [
[
[
"Ergocalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Butalbital"
]
],
[
[
"Ergocalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentobarbital"
... | Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Pentobarbital and Pentobarbital (Compound) resembles Butalbital (Compound)
Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital (Compound) resembles Buta... |
DB00312 | DB00902 | 1,023 | 104 | [
"DDInter1423",
"DDInter1168"
] | Pentobarbital | Methdilazine | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
1023,
24,
104
]
],
[
[
1023,
24,
13
],
[
13,
24,
104
]
],
[
[
1023,
24,
820
],
[
820,
1,
104
]
],
[
[
1023,
24,
537
],
[
537,
40... | [
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
... | Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Alime... |
DB00218 | DB01069 | 1,176 | 401 | [
"DDInter1247",
"DDInter1533"
] | Moxifloxacin | Promethazine | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Major | 2 | [
[
[
1176,
25,
401
]
],
[
[
1176,
25,
1264
],
[
1264,
63,
401
]
],
[
[
1176,
21,
28709
],
[
28709,
60,
401
]
],
[
[
1176,
24,
460
],
[
460,... | [
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
]
],
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} m... | Moxifloxacin may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Moxifloxacin (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Promethazine (C... |
DB01149 | DB08870 | 851 | 850 | [
"DDInter1274",
"DDInter228"
] | Nefazodone | Brentuximab vedotin | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
851,
24,
850
]
],
[
[
851,
63,
896
],
[
896,
24,
850
]
],
[
[
851,
64,
134
],
[
134,
24,
850
]
],
[
[
851,
25,
1468
],
[
1468,
6... | [
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
... | Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Nefazodone may lead to a major life threatening interaction when taken with Vinorelbine and Vinorelbine m... |
DB09143 | DB12500 | 313 | 283 | [
"DDInter1701",
"DDInter714"
] | Sonidegib | Fedratinib | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
313,
25,
283
]
],
[
[
313,
25,
351
],
[
351,
23,
283
]
],
[
[
313,
64,
1593
],
[
1593,
23,
283
]
],
[
[
313,
25,
1339
],
[
1339,
... | [
[
[
"Sonidegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Sonidegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may... | Sonidegib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Sonidegib may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a minor interaction... |
DB00678 | DB01143 | 240 | 923 | [
"DDInter1095",
"DDInter65"
] | Losartan | Amifostine | Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough simila... | A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia. | Moderate | 1 | [
[
[
240,
24,
923
]
],
[
[
240,
21,
28642
],
[
28642,
60,
923
]
],
[
[
240,
40,
1414
],
[
1414,
24,
923
]
],
[
[
240,
1,
911
],
[
911,
... | [
[
[
"Losartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifostine"
]
],
[
[
"Losartan",
"{u} (Compound) causes {v} (Side Effect)",
"Shock"
],
[
"Shock",
"{u} (Side Effect) is caused by {v} (C... | Losartan (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Amifostine (Compound)
Losartan (Compound) resembles Eprosartan (Compound) and Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Amifostine
Losartan (Compound) resembles Azilsartan medoxomil (Comp... |
DB08868 | DB11901 | 1,011 | 913 | [
"DDInter737",
"DDInter107"
] | Fingolimod | Apalutamide | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Major | 2 | [
[
[
1011,
25,
913
]
],
[
[
1011,
62,
112
],
[
112,
23,
913
]
],
[
[
1011,
25,
110
],
[
110,
62,
913
]
],
[
[
1011,
64,
600
],
[
600,
... | [
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Fingolimod",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Fingolimod may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Fingolimod may lead to a major life threatening interaction when taken with Polatuzumab vedotin and Polatuzum... |
DB00603 | DB12825 | 303 | 1,375 | [
"DDInter1137",
"DDInter1032"
] | Medroxyprogesterone acetate | Lefamulin | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Moderate | 1 | [
[
[
303,
24,
1375
]
],
[
[
303,
24,
159
],
[
159,
63,
1375
]
],
[
[
303,
64,
1101
],
[
1101,
24,
1375
]
],
[
[
303,
24,
98
],
[
98,
... | [
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Medroxyprogesterone acetate may lead to a major life threatening interaction when taken wi... |
DB00224 | DB01229 | 215 | 973 | [
"DDInter917",
"DDInter1378"
] | Indinavir | Paclitaxel (protein-bound) | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Major | 2 | [
[
[
215,
25,
973
]
],
[
[
215,
24,
310
],
[
310,
63,
973
]
],
[
[
215,
6,
7524
],
[
7524,
45,
973
]
],
[
[
215,
7,
4786
],
[
4786,
4... | [
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paclitaxel"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel... | Indinavir may lead to a major life threatening interaction when taken with Paclitaxel
Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Indinavir (Compound) bind... |
DB00295 | DB06207 | 475 | 910 | [
"DDInter1244",
"DDInter1667"
] | Morphine | Silodosin | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Silodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and prostatic urethra: the α<sub>1A</sub> subtype accounts for approximately 75% of α1-adrenocepto... | Moderate | 1 | [
[
[
475,
24,
910
]
],
[
[
475,
6,
8374
],
[
8374,
45,
910
]
],
[
[
475,
21,
28921
],
[
28921,
60,
910
]
],
[
[
475,
24,
1264
],
[
1264,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Silodosin"
]
],
[
[
"Morphine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Morphine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Silodosin (Compound)
Morphine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Silodosin (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cau... |
DB01105 | DB09268 | 222 | 1,662 | [
"DDInter1665",
"DDInter1464"
] | Sibutramine | Picosulfuric acid | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
222,
24,
1662
]
],
[
[
222,
64,
1164
],
[
1164,
24,
1662
]
],
[
[
222,
23,
484
],
[
484,
63,
1662
]
],
[
[
222,
63,
1027
],
[
1027,
... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trimipramine"
],
[
... | Sibutramine may lead to a major life threatening interaction when taken with Trimipramine and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Sibutramine may cause a minor interaction that can limit clinical effects when taken with Entrectinib and Entrectin... |
DB01211 | DB04844 | 609 | 843 | [
"DDInter393",
"DDInter1778"
] | Clarithromycin | Tetrabenazine | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Moderate | 1 | [
[
[
609,
24,
843
]
],
[
[
609,
62,
479
],
[
479,
40,
843
]
],
[
[
609,
18,
3106
],
[
3106,
57,
843
]
],
[
[
609,
21,
28698
],
[
28698,
... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
... | Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil (Compound) resembles Tetrabenazine (Compound)
Clarithromycin (Compound) downregulates DNAJA3 (Gene) and DNAJA3 (Gene) is downregulated by Tetrabenazine (Compound)
Clarithromycin (Compound) causes Insomni... |
DB01215 | DB09481 | 1,418 | 460 | [
"DDInter677",
"DDInter1113"
] | Estazolam | Magnesium carbonate | A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam. | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Minor | 0 | [
[
[
1418,
23,
460
]
],
[
[
1418,
63,
401
],
[
401,
23,
460
]
],
[
[
1418,
40,
1382
],
[
1382,
23,
460
]
],
[
[
1418,
1,
1563
],
[
1563,
... | [
[
[
"Estazolam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Estazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
... | Estazolam may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Estazolam (Compound) resembles Midazolam (Compound) and Midazolam may cause a minor interaction that c... |
DB00289 | DB01087 | 847 | 1,520 | [
"DDInter132",
"DDInter1520"
] | Atomoxetine | Primaquine | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve develop... | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Moderate | 1 | [
[
[
847,
24,
1520
]
],
[
[
847,
25,
1487
],
[
1487,
64,
1520
]
],
[
[
847,
6,
12523
],
[
12523,
45,
1520
]
],
[
[
847,
21,
28722
],
[
2872... | [
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
]
],
[
[
"Atomoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"... | Atomoxetine may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Primaquine
Atomoxetine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Primaquine (Compound)
Atomoxetine (Compound) causes ... |
DB00307 | DB06414 | 1,101 | 655 | [
"DDInter202",
"DDInter703"
] | Bexarotene | Etravirine | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Minor | 0 | [
[
[
1101,
23,
655
]
],
[
[
1101,
24,
786
],
[
786,
40,
655
]
],
[
[
1101,
6,
6017
],
[
6017,
45,
655
]
],
[
[
1101,
21,
28723
],
[
28723,
... | [
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Etravirine"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
],
[
... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine and Rilpivirine (Compound) resembles Etravirine (Compound)
Bexarotene (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Etravirine (Compound)
Bexarotene (Compound) causes Malnutrition (Side Effect) and Maln... |
DB00191 | DB00344 | 73 | 1,302 | [
"DDInter1447",
"DDInter1543"
] | Phentermine | Protriptyline | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Moderate | 1 | [
[
[
73,
24,
1302
]
],
[
[
73,
25,
109
],
[
109,
40,
1302
]
],
[
[
73,
6,
12523
],
[
12523,
45,
1302
]
],
[
[
73,
21,
29232
],
[
29232,
... | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protriptyline"
]
],
[
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duloxetine"
],
[
"Dulox... | Phentermine may lead to a major life threatening interaction when taken with Duloxetine and Duloxetine (Compound) resembles Protriptyline (Compound)
Phentermine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Protriptyline (Compound)
Phentermine (Compound) causes Urticaria (Side Effect) and Urticaria (Side... |
DB00374 | DB08931 | 1,061 | 947 | [
"DDInter1852",
"DDInter1600"
] | Treprostinil | Riociguat | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurre... | Moderate | 1 | [
[
[
1061,
24,
947
]
],
[
[
1061,
24,
1344
],
[
1344,
24,
947
]
],
[
[
1061,
63,
1214
],
[
1214,
24,
947
]
],
[
[
1061,
24,
1455
],
[
1455,... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Riociguat"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
... | Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Riociguat
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil an... |
DB11793 | DB15328 | 738 | 829 | [
"DDInter1297",
"DDInter1896"
] | Niraparib | Ubrogepant | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor ... | Moderate | 1 | [
[
[
738,
24,
829
]
],
[
[
738,
63,
1468
],
[
1468,
24,
829
]
],
[
[
738,
24,
124
],
[
124,
24,
829
]
],
[
[
738,
64,
1510
],
[
1510,
... | [
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
]
],
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
... | Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib m... |
DB00679 | DB09291 | 684 | 741 | [
"DDInter1796",
"DDInter1615"
] | Thioridazine | Rolapitant | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Major | 2 | [
[
[
684,
25,
741
]
],
[
[
684,
63,
506
],
[
506,
24,
741
]
],
[
[
684,
25,
1264
],
[
1264,
24,
741
]
],
[
[
684,
36,
401
],
[
401,
2... | [
[
[
"Thioridazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rolapitant"
]
],
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"... | Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Thioridazine may lead to a major life threatening interaction when taken with Doxepin and Doxepin ... |
DB01042 | DB01165 | 1,307 | 1,539 | [
"DDInter1144",
"DDInter1325"
] | Melphalan | Ofloxacin | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-con... | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Minor | 0 | [
[
[
1307,
23,
1539
]
],
[
[
1307,
62,
1467
],
[
1467,
1,
1539
]
],
[
[
1307,
23,
945
],
[
945,
40,
1539
]
],
[
[
1307,
23,
246
],
[
246,
... | [
[
[
"Melphalan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ofloxacin"
]
],
[
[
"Melphalan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enoxacin"
],
[
"Enox... | Melphalan may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin (Compound) resembles Ofloxacin (Compound)
Melphalan may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Ofloxacin (Compound)
Melphala... |
DB00397 | DB00543 | 1,466 | 87 | [
"DDInter1458",
"DDInter82"
] | Phenylpropanolamine | Amoxapine | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Moderate | 1 | [
[
[
1466,
24,
87
]
],
[
[
1466,
6,
2437
],
[
2437,
45,
87
]
],
[
[
1466,
21,
28741
],
[
28741,
60,
87
]
],
[
[
1466,
24,
959
],
[
959,
... | [
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
]
],
[
[
"Phenylpropanolamine",
"{u} (Compound) binds {v} (Gene)",
"SLC6A3"
],
[
"SLC6A3",
"{u} (Gene) is bound by... | Phenylpropanolamine (Compound) binds SLC6A3 (Gene) and SLC6A3 (Gene) is bound by Amoxapine (Compound)
Phenylpropanolamine (Compound) causes Agitation (Side Effect) and Agitation (Side Effect) is caused by Amoxapine (Compound)
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken... |
DB00451 | DB14491 | 542 | 428 | [
"DDInter1064",
"DDInter725"
] | Levothyroxine | Ferrous fumarate | Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quant... | Used in treatment of iron deficiency anemia. | Moderate | 1 | [
[
[
542,
24,
428
]
],
[
[
542,
23,
752
],
[
752,
23,
428
]
],
[
[
542,
24,
379
],
[
379,
24,
428
]
],
[
[
542,
40,
1152
],
[
1152,
2... | [
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Levothyroxine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
]... | Levothyroxine may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole a... |
DB01099 | DB13985 | 1,272 | 546 | [
"DDInter744",
"DDInter1108"
] | Flucytosine | Lutetium Lu 177 dotatate | A fluorinated cytosine analog that is used as an antifungal agent. | A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dot... | Moderate | 1 | [
[
[
1272,
24,
546
]
],
[
[
1272,
63,
50
],
[
50,
24,
546
]
],
[
[
1272,
24,
1683
],
[
1683,
24,
546
]
],
[
[
1272,
63,
629
],
[
629,
... | [
[
[
"Flucytosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Flucytosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazi... | Flucytosine may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Flucytosine may cause a moderate interaction that could exacerbate diseases when taken with... |
DB01168 | DB09074 | 1,053 | 1,362 | [
"DDInter1526",
"DDInter1327"
] | Procarbazine | Olaparib | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
1053,
24,
1362
]
],
[
[
1053,
64,
576
],
[
576,
24,
1362
]
],
[
[
1053,
24,
1683
],
[
1683,
24,
1362
]
],
[
[
1053,
63,
139
],
[
139,
... | [
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methadone"
],
[
"Methadone... | Procarbazine may lead to a major life threatening interaction when taken with Methadone and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may caus... |
DB00342 | DB00656 | 1,181 | 827 | [
"DDInter1770",
"DDInter1851"
] | Terfenadine | Trazodone | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and se... | Moderate | 1 | [
[
[
1181,
24,
827
]
],
[
[
1181,
24,
623
],
[
623,
40,
827
]
],
[
[
1181,
24,
1630
],
[
1630,
1,
827
]
],
[
[
1181,
25,
851
],
[
851,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trazodone"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
],
[
... | Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine and Quetiapine (Compound) resembles Trazodone (Compound)
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Trazodone (Compou... |
DB00872 | DB09030 | 1,080 | 840 | [
"DDInter438",
"DDInter1945"
] | Conivaptan | Vorapaxar | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Major | 2 | [
[
[
1080,
25,
840
]
],
[
[
1080,
25,
1017
],
[
1017,
63,
840
]
],
[
[
1080,
24,
1496
],
[
1496,
63,
840
]
],
[
[
1080,
25,
578
],
[
578,
... | [
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
]
],
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} ma... | Conivaptan may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib may cause a... |
DB00197 | DB11799 | 1,324 | 627 | [
"DDInter1881",
"DDInter205"
] | Troglitazone | Bictegravir | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet. | Moderate | 1 | [
[
[
1324,
24,
627
]
],
[
[
1324,
24,
1362
],
[
1362,
24,
627
]
],
[
[
1324,
24,
466
],
[
466,
63,
627
]
],
[
[
1324,
23,
1101
],
[
1101,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bictegravir"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Dar... |
DB00359 | DB00682 | 161 | 126 | [
"DDInter1721",
"DDInter1951"
] | Sulfadiazine | Warfarin | One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections. | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Major | 2 | [
[
[
161,
25,
126
]
],
[
[
161,
6,
3486
],
[
3486,
45,
126
]
],
[
[
161,
24,
663
],
[
663,
23,
126
]
],
[
[
161,
24,
1411
],
[
1411,
... | [
[
[
"Sulfadiazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
]
],
[
[
"Sulfadiazine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Warfa... | Sulfadiazine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Warfarin (Compound)
Sulfadiazine may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a minor interaction that can limit clinical effects when taken with Warfarin
Sulfadiazine may... |
DB00284 | DB01044 | 1,647 | 246 | [
"DDInter11",
"DDInter809"
] | Acarbose | Gatifloxacin | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Major | 2 | [
[
[
1647,
25,
246
]
],
[
[
1647,
24,
739
],
[
739,
1,
246
]
],
[
[
1647,
63,
1176
],
[
1176,
1,
246
]
],
[
[
1647,
24,
945
],
[
945,
... | [
[
[
"Acarbose",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxac... | Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gatifloxacin (Compound)
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Gatifloxacin (Co... |
DB00685 | DB00773 | 1,299 | 896 | [
"DDInter1887",
"DDInter702"
] | Trovafloxacin | Etoposide | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Minor | 0 | [
[
[
1299,
23,
896
]
],
[
[
1299,
21,
28681
],
[
28681,
60,
896
]
],
[
[
1299,
1,
739
],
[
739,
62,
896
]
],
[
[
1299,
1,
1467
],
[
1467,
... | [
[
[
"Trovafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Etoposide"
]
],
[
[
"Trovafloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Sid... | Trovafloxacin (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Etoposide (Compound)
Trovafloxacin (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Etoposide
Trovafloxacin (Compound)... |
DB06674 | DB10795 | 908 | 221 | [
"DDInter837",
"DDInter1486"
] | Golimumab | Poliovirus type 1 antigen (formaldehyde inactivated) | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a c... | Moderate | 1 | [
[
[
908,
24,
221
]
],
[
[
908,
25,
36
],
[
36,
24,
221
]
],
[
[
908,
64,
581
],
[
581,
24,
221
]
],
[
[
908,
63,
599
],
[
599,
24,
... | [
[
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Er... | Golimumab may lead to a major life threatening interaction when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Golimumab may lead to a major life threatening interaction when taken with Infliximab and ... |
DB00254 | DB00421 | 964 | 443 | [
"DDInter598",
"DDInter1707"
] | Doxycycline | Spironolactone | Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and... | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were disco... | Minor | 0 | [
[
[
964,
23,
443
]
],
[
[
964,
24,
126
],
[
126,
62,
443
]
],
[
[
964,
1,
1669
],
[
1669,
62,
443
]
],
[
[
964,
40,
1620
],
[
1620,
... | [
[
[
"Doxycycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Spironolactone"
]
],
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
... | Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Spironolactone
Doxycycline (Compound) resembles Minocycline (Compound) and Minocycline may cause a minor interaction that can li... |
DB01114 | DB01589 | 272 | 481 | [
"DDInter362",
"DDInter1552"
] | Chlorpheniramine | Quazepam | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Quazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors a... | Moderate | 1 | [
[
[
272,
24,
481
]
],
[
[
272,
63,
1216
],
[
1216,
1,
481
]
],
[
[
272,
24,
1418
],
[
1418,
1,
481
]
],
[
[
272,
63,
905
],
[
905,
4... | [
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
]... | Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Quazepam (Compound)
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Estazolam and Estazolam (Compound) resembles Quazepam (Comp... |
DB00405 | DB00794 | 128 | 759 | [
"DDInter517",
"DDInter1521"
] | Dexbrompheniramine | Primidone | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Moderate | 1 | [
[
[
128,
24,
759
]
],
[
[
128,
24,
697
],
[
697,
40,
759
]
],
[
[
128,
63,
362
],
[
362,
1,
759
]
],
[
[
128,
24,
157
],
[
157,
1,
... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbita... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital (Compound) resembles Primidone (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Pri... |
DB00827 | DB01229 | 646 | 973 | [
"DDInter383",
"DDInter1378"
] | Cinoxacin | Paclitaxel (protein-bound) | Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections. | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Minor | 0 | [
[
[
646,
23,
973
]
],
[
[
646,
21,
29310
],
[
29310,
60,
973
]
],
[
[
646,
25,
1220
],
[
1220,
63,
973
]
],
[
[
646,
62,
134
],
[
134,
... | [
[
[
"Cinoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Paclitaxel"
]
],
[
[
"Cinoxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Toxic epidermal necrolysis"
],
[
"Toxic epidermal necrolysis",
... | Cinoxacin may cause a minor interaction that can limit clinical effects when taken with Paclitaxel
Cinoxacin (Compound) causes Toxic epidermal necrolysis (Side Effect) and Toxic epidermal necrolysis (Side Effect) is caused by Paclitaxel (Compound)
Cinoxacin may lead to a major life threatening interaction when taken wi... |
DB01132 | DB09564 | 1,130 | 1,296 | [
"DDInter1472",
"DDInter930"
] | Pioglitazone | Insulin degludec | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
1130,
24,
1296
]
],
[
[
1130,
62,
1103
],
[
1103,
23,
1296
]
],
[
[
1130,
24,
659
],
[
659,
24,
1296
]
],
[
[
1130,
63,
104
],
[
104,
... | [
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Pioglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
... | Pioglitazone may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Insulin degludec
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and ... |
DB01285 | DB05679 | 708 | 1,683 | [
"DDInter445",
"DDInter1907"
] | Corticotropin | Ustekinumab | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
708,
24,
1683
]
],
[
[
708,
24,
1129
],
[
1129,
63,
1683
]
],
[
[
708,
64,
33
],
[
33,
24,
1683
]
],
[
[
708,
63,
409
],
[
409,
... | [
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e s... | Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen and Human adenovirus e serotype 4 strain cl-68578 antigen may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Corticotropin may lead... |
DB00327 | DB00704 | 421 | 267 | [
"DDInter890",
"DDInter1263"
] | Hydromorphone | Naltrexone | Hydromorphone is a pure opioid, a semi-synthetic hydrogenated ketone derivative of [morphine] that has been available clinically since 1920. Structurally, hydromorphone derived from [morphine] in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 a... | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Major | 2 | [
[
[
421,
36,
267
]
],
[
[
421,
1,
828
],
[
828,
25,
267
]
],
[
[
421,
1,
1235
],
[
1235,
40,
267
]
],
[
[
421,
35,
173
],
[
173,
1,
... | [
[
[
"Hydromorphone",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Naltrexone"
]
],
[
[
"Hydromorphone",
"{u} (Compound) resembles {v} (Compound)",
"Oxycodone"
],
[
"Oxycodone... | Hydromorphone (Compound) resembles Naltrexone (Compound) and
Hydromorphone (Compound) resembles Oxycodone (Compound) and Oxycodone may lead to a major life threatening interaction when taken with Naltrexone
Hydromorphone (Compound) resembles Hydrocodone (Compound) and Hydrocodone (Compound) resembles Naltrexone (Compou... |
DB00570 | DB00649 | 147 | 231 | [
"DDInter1936",
"DDInter1710"
] | Vinblastine | Stavudine | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. | Moderate | 1 | [
[
[
147,
24,
231
]
],
[
[
147,
24,
1477
],
[
1477,
40,
231
]
],
[
[
147,
63,
139
],
[
139,
1,
231
]
],
[
[
147,
7,
14025
],
[
14025,
... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stavudine"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telbivudine"
],
[
... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Telbivudine and Telbivudine (Compound) resembles Stavudine (Compound)
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine (Compound) resembles Stavudine (Compound... |
DB00398 | DB12130 | 79 | 1,017 | [
"DDInter1702",
"DDInter1094"
] | Sorafenib | Lorlatinib | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
79,
24,
1017
]
],
[
[
79,
24,
1612
],
[
1612,
23,
1017
]
],
[
[
79,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
79,
23,
1459
],
[
1459,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
... | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarote... |
DB01136 | DB09104 | 772 | 286 | [
"DDInter305",
"DDInter1118"
] | Carvedilol | Magnesium hydroxide | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Minor | 0 | [
[
[
772,
23,
286
]
],
[
[
772,
24,
820
],
[
820,
23,
286
]
],
[
[
772,
63,
401
],
[
401,
23,
286
]
],
[
[
772,
64,
688
],
[
688,
24,... | [
[
[
"Carvedilol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
... | Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine... |
DB00222 | DB01299 | 245 | 698 | [
"DDInter825",
"DDInter1722"
] | Glimepiride | Sulfadoxine | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections. | Moderate | 1 | [
[
[
245,
24,
698
]
],
[
[
245,
24,
1247
],
[
1247,
40,
698
]
],
[
[
245,
24,
161
],
[
161,
1,
698
]
],
[
[
245,
63,
1560
],
[
1560,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfadoxine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
],... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole (Compound) resembles Sulfadoxine (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Sulfadiazine and Sulfadiazine (Compound) resembles Sul... |
DB00029 | DB00939 | 25 | 1,338 | [
"DDInter99",
"DDInter1135"
] | Anistreplase | Meclofenamic acid | Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl gro... | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Moderate | 1 | [
[
[
25,
24,
1338
]
],
[
[
25,
24,
1479
],
[
1479,
63,
1338
]
],
[
[
25,
24,
1347
],
[
1347,
24,
1338
]
],
[
[
25,
25,
1226
],
[
1226,
... | [
[
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic ... | Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Anistreplase may cause a moderate interaction that could exacerbate diseases when t... |
DB01072 | DB09154 | 915 | 1,475 | [
"DDInter129",
"DDInter1686"
] | Atazanavir | Sodium citrate | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Sodium citrate is the sodium salt of citric acid. It is white, crystalline powder or white, granular crystals, slightly deliquescent in moist air, freely soluble in water, practically insoluble in alcohol. Like citric acid, it has a sour taste. From the medical point of view, it is used as alkalinizing agent. It works ... | Moderate | 1 | [
[
[
915,
24,
1475
]
],
[
[
915,
25,
263
],
[
263,
23,
1475
]
],
[
[
915,
24,
1411
],
[
1411,
23,
1475
]
],
[
[
915,
63,
959
],
[
959,
... | [
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium citrate"
]
],
[
[
"Atazanavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Axitinib"
],
[
"Axitinib... | Atazanavir may lead to a major life threatening interaction when taken with Axitinib and Axitinib may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause ... |
DB00800 | DB00860 | 572 | 891 | [
"DDInter720",
"DDInter1513"
] | Fenoldopam | Prednisolone | A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation. | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Moderate | 1 | [
[
[
572,
24,
891
]
],
[
[
572,
63,
175
],
[
175,
40,
891
]
],
[
[
572,
63,
167
],
[
167,
1,
891
]
],
[
[
572,
24,
617
],
[
617,
40,
... | [
[
[
"Fenoldopam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Fenoldopam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
... | Fenoldopam may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisolone (Compound)
Fenoldopam may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Predni... |
DB01080 | DB01142 | 855 | 1,264 | [
"DDInter1933",
"DDInter593"
] | Vigabatrin | Doxepin | Vigabatrin is an analog of gamma-aminobutyric acid ([GABA]), the main inhibitory neurotransmitter in the central nervous system, used in the treatment of refractory seizures and infantile spasms. It irreversibly inhibits the enzyme responsible for GABA metabolism, thereby increasing levels of circulating GABA. Although... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
855,
24,
1264
]
],
[
[
855,
63,
401
],
[
401,
24,
1264
]
],
[
[
855,
24,
649
],
[
649,
63,
1264
]
],
[
[
855,
21,
29226
],
[
29226,
... | [
[
[
"Vigabatrin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Vigabatrin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
... | Vigabatrin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Vigabatrin may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofe... |
DB01285 | DB09045 | 708 | 52 | [
"DDInter445",
"DDInter607"
] | Corticotropin | Dulaglutide | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
708,
24,
52
]
],
[
[
708,
63,
170
],
[
170,
23,
52
]
],
[
[
708,
24,
178
],
[
178,
24,
52
]
],
[
[
708,
63,
674
],
[
674,
24,
... | [
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
... | Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide a... |
DB00851 | DB00987 | 611 | 1,224 | [
"DDInter463",
"DDInter461"
] | Dacarbazine | Cytarabine (liposomal) | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | Cytarabine can cause developmental toxicity according to an independent committee of scientific and health experts. | Moderate | 1 | [
[
[
611,
24,
1224
]
],
[
[
611,
5,
11555
],
[
11555,
44,
1224
]
],
[
[
611,
23,
872
],
[
872,
62,
1224
]
],
[
[
611,
23,
739
],
[
739,
... | [
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cytarabine"
]
],
[
[
"Dacarbazine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Dise... | Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine
Dacarbazine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Cytarabine (Compound)
Dacarbazine may cause a minor interaction that can limit clinical effects when taken with... |
DB01238 | DB06292 | 673 | 549 | [
"DDInter118",
"DDInter474"
] | Aripiprazole | Dapagliflozin | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
673,
24,
549
]
],
[
[
673,
24,
1344
],
[
1344,
40,
549
]
],
[
[
673,
6,
8374
],
[
8374,
45,
549
]
],
[
[
673,
21,
29222
],
[
29222,
... | [
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]... | Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Aripiprazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dapagliflozin (Compound)
Aripiprazole (Compound) causes Hypoglycaemia (Side... |
DB09389 | DB14568 | 517 | 982 | [
"DDInter1315",
"DDInter1000"
] | Norgestrel | Ivosidenib | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
517,
24,
982
]
],
[
[
517,
64,
1101
],
[
1101,
23,
982
]
],
[
[
517,
25,
1476
],
[
1476,
24,
982
]
],
[
[
517,
24,
159
],
[
159,
... | [
[
[
"Norgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Norgestrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene... | Norgestrel may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Norgestrel may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate intera... |
DB00196 | DB00570 | 600 | 147 | [
"DDInter743",
"DDInter1936"
] | Fluconazole | Vinblastine | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Moderate | 1 | [
[
[
600,
24,
147
]
],
[
[
600,
24,
134
],
[
134,
24,
147
]
],
[
[
600,
6,
8374
],
[
8374,
45,
147
]
],
[
[
600,
18,
7847
],
[
7847,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
... | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine
Fluconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vinblastine (Compound)
Fluconazole ... |
DB00604 | DB00640 | 1,425 | 1,585 | [
"DDInter385",
"DDInter31"
] | Cisapride | Adenosine | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole]... | Major | 2 | [
[
[
1425,
25,
1585
]
],
[
[
1425,
24,
578
],
[
578,
62,
1585
]
],
[
[
1425,
25,
477
],
[
477,
63,
1585
]
],
[
[
1425,
64,
521
],
[
521,
... | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Adenosine"
]
],
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
... | Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Adenosine
Cisapride may lead to a major life threatening interaction when taken with Cilostazol and Cilostazol may cause a mod... |
DB00284 | DB01069 | 1,647 | 401 | [
"DDInter11",
"DDInter1533"
] | Acarbose | Promethazine | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
1647,
24,
401
]
],
[
[
1647,
24,
146
],
[
146,
24,
401
]
],
[
[
1647,
24,
820
],
[
820,
63,
401
]
],
[
[
1647,
21,
28787
],
[
28787,
... | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
],
[
... | Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Ali... |
DB00434 | DB09068 | 13 | 1,427 | [
"DDInter459",
"DDInter1948"
] | Cyproheptadine | Vortioxetine | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin r... | Moderate | 1 | [
[
[
13,
24,
1427
]
],
[
[
13,
24,
1311
],
[
1311,
24,
1427
]
],
[
[
13,
63,
475
],
[
475,
24,
1427
]
],
[
[
13,
24,
1264
],
[
1264,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
... | Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Mor... |
DB00701 | DB00912 | 1,091 | 473 | [
"DDInter90",
"DDInter1581"
] | Amprenavir | Repaglinide | Amprenavir is a protease inhibitor used to treat HIV infection. | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
1091,
24,
473
]
],
[
[
1091,
6,
3486
],
[
3486,
45,
473
]
],
[
[
1091,
21,
28883
],
[
28883,
60,
473
]
],
[
[
1091,
23,
609
],
[
609,
... | [
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Amprenavir",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)"... | Amprenavir (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Repaglinide (Compound)
Amprenavir (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Repaglinide (Compound)
Amprenavir may cause a minor interaction that can limit clinical effects when taken with Clarithromy... |
DB01043 | DB04843 | 108 | 1,511 | [
"DDInter1146",
"DDInter1149"
] | Memantine | Mepenzolate | Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in ... | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
108,
24,
1511
]
],
[
[
108,
24,
537
],
[
537,
24,
1511
]
],
[
[
108,
63,
1192
],
[
1192,
24,
1511
]
],
[
[
108,
21,
28975
],
[
28975,
... | [
[
[
"Memantine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Memantine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
... | Memantine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Memantine may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and Glyco... |
DB00653 | DB01017 | 544 | 1,669 | [
"DDInter1120",
"DDInter1224"
] | Magnesium sulfate | Minocycline | A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions... | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetr... | Moderate | 1 | [
[
[
544,
24,
1669
]
],
[
[
544,
63,
1572
],
[
1572,
1,
1669
]
],
[
[
544,
63,
1545
],
[
1545,
40,
1669
]
],
[
[
544,
24,
1620
],
[
1620,
... | [
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minocycline"
]
],
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycli... | Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline (Compound) resembles Minocycline (Compound)
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Oxytetracycline and Oxytetracycline (Compound)... |
DB06643 | DB11760 | 1,136 | 119 | [
"DDInter500",
"DDInter1742"
] | Denosumab | Talazoparib | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was app... | Moderate | 1 | [
[
[
1136,
24,
119
]
],
[
[
1136,
63,
66
],
[
66,
24,
119
]
],
[
[
1136,
24,
713
],
[
713,
24,
119
]
],
[
[
1136,
24,
1619
],
[
1619,
... | [
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
... | Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and ... |
DB00631 | DB00712 | 372 | 1,274 | [
"DDInter405",
"DDInter763"
] | Clofarabine | Flurbiprofen | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Moderate | 1 | [
[
[
372,
24,
1274
]
],
[
[
372,
24,
935
],
[
935,
63,
1274
]
],
[
[
372,
63,
1523
],
[
1523,
24,
1274
]
],
[
[
372,
7,
7720
],
[
7720,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
],
... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Lab... |
DB00373 | DB00981 | 461 | 1,528 | [
"DDInter1809",
"DDInter1462"
] | Timolol | Physostigmine | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective ag... | A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. | Moderate | 1 | [
[
[
461,
24,
1528
]
],
[
[
461,
5,
11595
],
[
11595,
44,
1528
]
],
[
[
461,
21,
28658
],
[
28658,
60,
1528
]
],
[
[
461,
24,
1511
],
[
151... | [
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Timolol",
"{u} (Compound) treats {v} (Disease)",
"glaucoma"
],
[
"glaucoma",
"{u} (Disease) is treated by {v} (C... | Timolol (Compound) treats glaucoma (Disease) and glaucoma (Disease) is treated by Physostigmine (Compound)
Timolol (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Physostigmine (Compound)
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate... |
DB00934 | DB01075 | 413 | 1,376 | [
"DDInter1124",
"DDInter569"
] | Maprotiline | Diphenhydramine | Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does n... | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Moderate | 1 | [
[
[
413,
24,
1376
]
],
[
[
413,
24,
649
],
[
649,
63,
1376
]
],
[
[
413,
64,
11
],
[
11,
1,
1376
]
],
[
[
413,
63,
128
],
[
128,
24,... | [
[
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
... | Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Maprotiline may lead to a major life threatening interaction when taken with Toremifene and Toremifene (Co... |
DB00019 | DB01181 | 1,257 | 1,532 | [
"DDInter1405",
"DDInter906"
] | Pegfilgrastim | Ifosfamide | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti... | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
1257,
24,
1532
]
],
[
[
1257,
24,
1648
],
[
1648,
24,
1532
]
],
[
[
1257,
24,
1330
],
[
1330,
63,
1532
]
],
[
[
1257,
25,
1064
],
[
10... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab and... |
DB09080 | DB09330 | 144 | 985 | [
"DDInter1331",
"DDInter1352"
] | Olodaterol | Osimertinib | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
144,
24,
985
]
],
[
[
144,
62,
1247
],
[
1247,
23,
985
]
],
[
[
144,
63,
480
],
[
480,
24,
985
]
],
[
[
144,
24,
1032
],
[
1032,
... | [
[
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Olodaterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Olodaterol may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Formoterol a... |
DB00087 | DB08904 | 599 | 375 | [
"DDInter41",
"DDInter342"
] | Alemtuzumab | Certolizumab pegol | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Moderate | 1 | [
[
[
599,
24,
375
]
],
[
[
599,
24,
200
],
[
200,
63,
375
]
],
[
[
599,
24,
1554
],
[
1554,
24,
375
]
],
[
[
599,
63,
491
],
[
491,
2... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00029 | DB09030 | 25 | 840 | [
"DDInter99",
"DDInter1945"
] | Anistreplase | Vorapaxar | Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl gro... | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Major | 2 | [
[
[
25,
25,
840
]
],
[
[
25,
23,
944
],
[
944,
62,
840
]
],
[
[
25,
24,
383
],
[
383,
24,
840
]
],
[
[
25,
24,
1496
],
[
1496,
63,
... | [
[
[
"Anistreplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
]
],
[
[
"Anistreplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile"... | Anistreplase may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Vorapaxar
Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate and... |
DB00514 | DB01589 | 506 | 481 | [
"DDInter527",
"DDInter1552"
] | Dextromethorphan | Quazepam | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Quazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors a... | Moderate | 1 | [
[
[
506,
24,
481
]
],
[
[
506,
24,
1216
],
[
1216,
1,
481
]
],
[
[
506,
63,
523
],
[
523,
1,
481
]
],
[
[
506,
63,
905
],
[
905,
40,... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
]... | Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Quazepam (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Alprazolam and Alprazolam (Compound) resembles Quazepam (Co... |
DB01138 | DB09291 | 804 | 741 | [
"DDInter1726",
"DDInter1615"
] | Sulfinpyrazone | Rolapitant | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Moderate | 1 | [
[
[
804,
24,
741
]
],
[
[
804,
24,
1135
],
[
1135,
23,
741
]
],
[
[
804,
24,
159
],
[
159,
63,
741
]
],
[
[
804,
24,
1496
],
[
1496,
... | [
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
... | Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Rolapitant
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and... |
DB05773 | DB06317 | 1,047 | 1,626 | [
"DDInter1848",
"DDInter630"
] | Trastuzumab emtansine | Elotuzumab | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family... | Moderate | 1 | [
[
[
1047,
24,
1626
]
],
[
[
1047,
63,
973
],
[
973,
24,
1626
]
],
[
[
1047,
24,
310
],
[
310,
63,
1626
]
],
[
[
1047,
25,
1468
],
[
1468,
... | [
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pacli... | Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with... |
DB01191 | DB05773 | 1,039 | 1,047 | [
"DDInter518",
"DDInter1848"
] | Dexfenfluramine | Trastuzumab emtansine | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Moderate | 1 | [
[
[
1039,
24,
1047
]
],
[
[
1039,
63,
848
],
[
848,
24,
1047
]
],
[
[
1039,
25,
643
],
[
643,
63,
1047
]
],
[
[
1039,
64,
1230
],
[
1230,
... | [
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibupro... | Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Dexfenfluramine may lead to a major life threatening interaction when taken with Desvenlafaxine an... |
DB00719 | DB00835 | 1,219 | 100 | [
"DDInter149",
"DDInter245"
] | Azatadine | Brompheniramine | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
1219,
24,
100
]
],
[
[
1219,
63,
128
],
[
128,
24,
100
]
],
[
[
1219,
24,
211
],
[
211,
63,
100
]
],
[
[
1219,
6,
8374
],
[
8374,
... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
... | Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with To... |
DB01259 | DB09034 | 392 | 1,313 | [
"DDInter1024",
"DDInter1733"
] | Lapatinib | Suvorexant | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Moderate | 1 | [
[
[
392,
24,
1313
]
],
[
[
392,
23,
1135
],
[
1135,
62,
1313
]
],
[
[
392,
63,
1213
],
[
1213,
24,
1313
]
],
[
[
392,
24,
1619
],
[
1619,
... | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Lapatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"... | Lapatinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Suvorexant
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may c... |
DB00635 | DB09065 | 1,573 | 760 | [
"DDInter1515",
"DDInter424"
] | Prednisone | Cobicistat | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
1573,
24,
760
]
],
[
[
1573,
63,
1101
],
[
1101,
23,
760
]
],
[
[
1573,
24,
555
],
[
555,
23,
760
]
],
[
[
1573,
62,
523
],
[
523,
... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Netupitant and Netupita... |
DB00970 | DB08904 | 0 | 375 | [
"DDInter466",
"DDInter342"
] | Dactinomycin | Certolizumab pegol | A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also d... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Major | 2 | [
[
[
0,
25,
375
]
],
[
[
0,
63,
1461
],
[
1461,
23,
375
]
],
[
[
0,
24,
200
],
[
200,
63,
375
]
],
[
[
0,
63,
66
],
[
66,
24,
3... | [
[
[
"Dactinomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Dactinomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Candida albic... |
DB00218 | DB00262 | 1,176 | 552 | [
"DDInter1247",
"DDInter302"
] | Moxifloxacin | Carmustine | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | Minor | 0 | [
[
[
1176,
23,
552
]
],
[
[
1176,
21,
28817
],
[
28817,
60,
552
]
],
[
[
1176,
1,
739
],
[
739,
62,
552
]
],
[
[
1176,
23,
377
],
[
377,
... | [
[
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Carmustine"
]
],
[
[
"Moxifloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Vision blurred"
],
[
"Vision blurred",
"{u} (Side Eff... | Moxifloxacin (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Carmustine (Compound)
Moxifloxacin (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Carmustine
Moxifloxacin may cause a min... |
DB04865 | DB11952 | 4 | 800 | [
"DDInter1335",
"DDInter612"
] | Omacetaxine mepesuccinate | Duvelisib | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Moderate | 1 | [
[
[
4,
24,
800
]
],
[
[
4,
24,
310
],
[
310,
24,
800
]
],
[
[
4,
24,
1476
],
[
1476,
63,
800
]
],
[
[
4,
63,
663
],
[
663,
24,
... | [
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when t... |
DB08827 | DB08881 | 990 | 868 | [
"DDInter1085",
"DDInter1925"
] | Lomitapide | Vemurafenib | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
990,
25,
868
]
],
[
[
990,
6,
8374
],
[
8374,
45,
868
]
],
[
[
990,
54,
19133
],
[
19133,
15,
868
]
],
[
[
990,
21,
28847
],
[
28847,
... | [
[
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Lomitapide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vemura... | Lomitapide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Lomitapide (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class) and P-Glycoprotein Inhibitors (Pharmacologic Class) includes Vemurafenib (Compound)
Lomitapide (Compound) causes Eye disorder (Side Effect) ... |
DB06016 | DB09268 | 1,508 | 1,662 | [
"DDInter300",
"DDInter1464"
] | Cariprazine | Picosulfuric acid | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
1508,
24,
1662
]
],
[
[
1508,
24,
484
],
[
484,
63,
1662
]
],
[
[
1508,
63,
597
],
[
597,
24,
1662
]
],
[
[
1508,
24,
129
],
[
129,
... | [
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]... | Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Chloramphe... |
DB00470 | DB06414 | 530 | 655 | [
"DDInter601",
"DDInter703"
] | Dronabinol | Etravirine | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Moderate | 1 | [
[
[
530,
24,
655
]
],
[
[
530,
6,
4973
],
[
4973,
45,
655
]
],
[
[
530,
21,
28883
],
[
28883,
60,
655
]
],
[
[
530,
24,
1033
],
[
1033,
... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Dronabinol",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Dronabinol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Etravirine (Compound)
Dronabinol (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Etravirine (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and... |
DB00425 | DB11837 | 558 | 1,297 | [
"DDInter1970",
"DDInter1351"
] | Zolpidem | Osilodrostat | Zolpidem, also known as _Ambien_, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the duration of s... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
558,
24,
1297
]
],
[
[
558,
24,
222
],
[
222,
23,
1297
]
],
[
[
558,
63,
353
],
[
353,
24,
1297
]
],
[
[
558,
24,
401
],
[
401,
... | [
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseo... |
DB00333 | DB00662 | 576 | 717 | [
"DDInter1166",
"DDInter1873"
] | Methadone | Trimethobenzamide | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Moderate | 1 | [
[
[
576,
24,
717
]
],
[
[
576,
25,
1425
],
[
1425,
40,
717
]
],
[
[
576,
21,
29648
],
[
29648,
60,
717
]
],
[
[
576,
35,
1594
],
[
1594,
... | [
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Methadone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
],
[
"Cisapr... | Methadone may lead to a major life threatening interaction when taken with Cisapride and Cisapride (Compound) resembles Trimethobenzamide (Compound)
Methadone (Compound) causes Disorientation (Side Effect) and Disorientation (Side Effect) is caused by Trimethobenzamide (Compound)
Methadone (Compound) resembles Doxylami... |
DB01208 | DB01259 | 945 | 392 | [
"DDInter1705",
"DDInter1024"
] | Sparfloxacin | Lapatinib | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Major | 2 | [
[
[
945,
25,
392
]
],
[
[
945,
6,
4973
],
[
4973,
45,
392
]
],
[
[
945,
18,
3385
],
[
3385,
57,
392
]
],
[
[
945,
21,
28688
],
[
28688,
... | [
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
]
],
[
[
"Sparfloxacin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Lapati... | Sparfloxacin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Sparfloxacin (Compound) downregulates SDC1 (Gene) and SDC1 (Gene) is downregulated by Lapatinib (Compound)
Sparfloxacin (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Lapatinib (Compound)
Spa... |
DB00281 | DB00373 | 608 | 461 | [
"DDInter1066",
"DDInter1809"
] | Lidocaine | Timolol | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anest... | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective ag... | Moderate | 1 | [
[
[
608,
24,
461
]
],
[
[
608,
24,
729
],
[
729,
40,
461
]
],
[
[
608,
10,
11576
],
[
11576,
44,
461
]
],
[
[
608,
6,
4973
],
[
4973,
... | [
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
],
[
"... | Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol (Compound) resembles Timolol (Compound)
Lidocaine (Compound) palliates coronary artery disease (Disease) and coronary artery disease (Disease) is treated by Timolol (Compound)
Lidocaine (Compound) binds A... |
DB08890 | DB09020 | 16 | 28 | [
"DDInter1069",
"DDInter212"
] | Linaclotide | Bisacodyl | Linaclotide is a synthetic 14-amino acid cyclic peptide and first-in-class guanylate cyclase-C (G-CC) agonist.[A260271, L47211] Linaclotide is structurally related to human guanylin and uroguanylin, paracrine peptide hormones that are endogenous activators of GC-C. It is also a homolog of a heat-stable enterotoxin deri... | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Minor | 0 | [
[
[
16,
23,
28
]
],
[
[
16,
62,
355
],
[
355,
24,
28
]
],
[
[
16,
23,
286
],
[
286,
63,
28
]
],
[
[
16,
62,
355
],
[
355,
54,
... | [
[
[
"Linaclotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bisacodyl"
]
],
[
[
"Linaclotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lactulose"
],
[
... | Linaclotide may cause a minor interaction that can limit clinical effects when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Linaclotide may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Ma... |
DB13074 | DB15093 | 877 | 1,654 | [
"DDInter1110",
"DDInter1698"
] | Macimorelin | Somapacitan | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
877,
24,
1654
]
],
[
[
877,
63,
176
],
[
176,
24,
1654
]
],
[
[
877,
64,
351
],
[
351,
24,
1654
]
],
[
[
877,
63,
1101
],
[
1101,
... | [
[
[
"Macimorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Macimorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],... | Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Macimorelin may lead to a major life threatening interaction when taken with Ribociclib and Riboci... |
DB00631 | DB06608 | 372 | 1,185 | [
"DDInter405",
"DDInter1739"
] | Clofarabine | Tafenoquine | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Tafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group.[A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria. Tafenoq... | Moderate | 1 | [
[
[
372,
24,
1185
]
],
[
[
372,
24,
1364
],
[
1364,
24,
1185
]
],
[
[
372,
24,
1247
],
[
1247,
40,
10
],
[
10,
24,
1185
]
],
[
[
372,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tafenoquine"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanfacine"
],
[... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Guanfacine and Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Tafenoquine
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole a... |
DB00295 | DB01142 | 475 | 1,264 | [
"DDInter1244",
"DDInter593"
] | Morphine | Doxepin | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
475,
24,
1264
]
],
[
[
475,
25,
508
],
[
508,
24,
1264
]
],
[
[
475,
24,
401
],
[
401,
24,
1264
]
],
[
[
475,
24,
649
],
[
649,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promazine"
],
[
"Promazine",
... | Morphine may lead to a major life threatening interaction when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a mod... |
DB05773 | DB12364 | 1,047 | 1,421 | [
"DDInter1848",
"DDInter200"
] | Trastuzumab emtansine | Betrixaban | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Major | 2 | [
[
[
1047,
25,
1421
]
],
[
[
1047,
63,
1091
],
[
1091,
24,
1421
]
],
[
[
1047,
24,
41
],
[
41,
24,
1421
]
],
[
[
1047,
25,
990
],
[
990,
... | [
[
[
"Trastuzumab emtansine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
],
... | Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00658 | DB11943 | 965 | 255 | [
"DDInter1663",
"DDInter495"
] | Sevelamer | Delafloxacin | Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel. | Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in t... | Moderate | 1 | [
[
[
965,
24,
255
]
],
[
[
965,
24,
1096
],
[
1096,
24,
255
]
],
[
[
965,
21,
28787
],
[
28787,
60,
1144
],
[
1144,
25,
255
]
],
[
[
965,
... | [
[
[
"Sevelamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delafloxacin"
]
],
[
[
"Sevelamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
... | Sevelamer may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin
Sevelamer (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Na... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.